Objective: Major adverse limb events (MALEs) and major adverse cardiovascular events (MACEs) at 30 days provide standardized metrics for comparison and have been adopted by the Society for Vascular Surgery's objective performance goals for critical limb ischemia. However, MALEs and MACEs have not been widely adopted within the claudication population, and the comparative outcomes after lower extremity bypass (LEB) and infrainguinal endovascular intervention (IEI) remain unclear. The purpose of this study was to compare MALEs and MACEs after LEB and IEI in a contemporary national cohort and to determine predictors of MALEs and MACEs after revascularization for claudication.
Lower extremity peripheral arterial disease (PAD) is a common syndrome worldwide and affects approximately 8 million patients in the United States. 1 Claudication has traditionally been treated conservatively with risk factor modification and supervised exercise programs; revascularization procedures have typically been reserved for those patients with severe disability from their symptoms and a favorable risk-benefit ratio for procedural intervention. [1] [2] [3] Revascularization can be
performed through either open lower extremity bypass (LEB) or infrainguinal endovascular intervention (IEI), which has gained widespread acceptance during the past several decades. 2, 4 Because IEI has lower periprocedural morbidity and mortality compared with open LEB, increasing numbers of patients with claudication are being treated with IEI as first-line therapy. 5, 6 However, there remains limited high-quality evidence to guide the optimal revascularization strategy in claudicants.
The majority of the current data are limited by heterogeneous study cohorts in which LEB and IEI have been compared in cohorts composed of both claudicants and patients with critical limb ischemia (CLI). In addition, the use of inconsistent definitions of end points and outcome measures has significantly limited the ability to compare treatment strategies across different studies and populations. The Society for Vascular Surgery objective performance goals (OPGs) established standardized metrics for comparison of 30-day outcomes after revascularization procedures in CLI patients. 7, 8 These OPGs established expected rates of major adverse limb events (MALEs), defined as either major amputation of the revascularized limb or reintervention on the revascularized segment. In addition, they set goals for major adverse cardiovascular events (MACEs), defined as cerebrovascular accident (CVA), myocardial infarction (MI), or death. The OPGs were created to compare outcomes of revascularization almost exclusively in the CLI population. The expected 30-day rates of MALEs and MACEs after revascularizations for claudication are not well known and OPGs could not be established. The National Surgical Quality Improvement Program (NSQIP) is a validated database that provides information regarding a national sampling of cases, including 30-day follow-up data. [9] [10] [11] In 2011, vascular targeted modules were added to the existing Participant Use Data File, expanding the database and accruing data on vascular-related patient variables as well as limb and cardiovascular outcomes. The goal of this study was to compare MALEs and MACEs after LEB and IEI to help in starting to define OPGs for these patients as well as to determine the factors predictive of MALEs and MACEs after revascularizations performed for claudication.
METHODS
The NSQIP vascular targeted Participant Use Data Files (2011-2014) for both LEB and IEI procedures were merged to obtain a representative national data set. All emergent procedures and those performed for CLI or asymptomatic peripheral vascular disease were excluded.
The primary outcomes were MALEs and MACEs within 30 days. MALE was defined as untreated loss of patency of the revascularization, reintervention on the revascularized segment, or major amputation (above or below the knee) of the revascularized limb. MACE was defined as CVA, MI, or death. Secondary outcomes included the individual component outcomes of MALEs (untreated loss of patency of the revascularization, reintervention on the revascularization, major amputation) and MACEs (stroke/MI [a combined outcome variable] and death). Additional secondary outcomes included the operative complications of deep incisional surgical site infection, bleeding, acute renal failure, discharge to home, readmission, and return to operating room. Appropriate parametric and nonparametric statistical tests were used, including c 2 test, independent t-test, and MannWhitney U test, to compare LEB and IEI cases. Multivariable logistic regression was then performed to identify predictors of MALEs and MACEs. The decision was made a priori to include the most significant predictors from univariate analysis up to a total of 1 predictor for every 10 events in the model. Statistical significance was set to P < .05. Statistical analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC). Informed consent was not obtained from patients as The University of Virginia Institutional Review Board exempted all studies using the deidentified NSQIP data set.
RESULTS

Patients.
A total of 13,294 LEB and IEI procedures were identified in the 2011 to 2014 NSQIP vascular targeted modules. Of these, 3925 were performed for claudication, of which 2155 (54.9%) were LEB and 1770 (45.1%) were IEI. At baseline, these groups had significant differences in many preoperative characteristics (Table I) . LEB patients were more commonly younger, male, white, and highrisk American Society of Anesthesiologists class, and they had history of tobacco use and chronic obstructive pulmonary disease (COPD). They were also more likely than IEI patients to be undergoing revascularization of an infrageniculate arterial segment (21.8% vs 9.5%; P < .0001). IEI patients were more likely to have a history of bleeding disorders, diabetes, and dialysis dependence and were more frequently taking antiplatelet, antihypertensive, and statin medications. IEI patients also had Recommendation: Open revascularization in claudicants should be performed selectively because of the increased risk of early cardiac complications. a higher history of prior percutaneous vascular interventions than those who were undergoing LEB (24.3% vs 15.7%; P < .0001).
ARTICLE HIGHLIGHTS
Procedures. Of the procedures performed for claudication (Table II) , 3288 (83.7%) were femoropopliteal revascularizations; the remaining 637 (16.3%) were completed on infrageniculate arterial targets. Of the total operations, 42.9% were LEB and 40.8% were IEI performed on femoropopliteal targets; 12% were LEB and 4.3% were IEI performed on infrageniculate targets.
Primary end points. At 30 days, MALEs were similar in LEB and IEI groups (4.0% LEB vs 3.2% IEI; P ¼ .17), with no difference in any individual component outcome of MALEs (Table III) . On multivariable logistic regression, independent predictors of MALEs (Table IV) MACEs were significantly higher in the LEB group (2.0% LEB vs 1.0% IEI; P ¼ .01) at 30 days (Table III) . This was driven primarily by a significantly higher rate of CVA and MI (1.8% LEB vs 0.7% IEI; P ¼ .003). There was no difference in mortality between groups (0.5% LEB vs 0.4% IEI; P ¼ .6). On multivariable logistic regression, revascularization approach with LEB was an independent predictor of MACEs (OR, 2.1; P ¼ .01; Table V ). Other independent predictors of MACEs included a history of COPD (OR, 2.2; P ¼ .01), dialysis dependence (OR, 4.4; P ¼ .003), and diabetes (OR, 1.9; P ¼ .02).
Secondary end points. Operative complications were different between LEB and IEI groups (Table VI) , with LEB patients having a higher incidence of deep incisional surgical site infection (1.5% LEB vs 0.2% IEI; P < .0001), bleeding (11.7% LEB vs 2.8% IEI; P < .0001), and return to operating room (7.9% LEB vs 4.9% IEI; P ¼ .0001). LEB patients also had lower rates of discharge to home (90.4% LEB vs 97.7% IEI; P < .0001). Our results are consistent with those of previous studies demonstrating that patients with more comorbid disease and thus higher surgical risk are often primarily considered for IEI. 5 As a result, it is not surprising that the LEB and IEI groups in this study had many baseline differences. Patients who underwent IEI were older and more likely to have significant cardiac risk factors including diabetes, hypertension, and dialysis dependence. The LEB group did, however, have more smoking history and pulmonary disease. This study identified comparable rates of 30-day MALEs in the LEB and IEI groups at 4% and 3.2%, respectively. Although these rates are surprisingly high for patients presenting only with claudication, the data show that this is driven primarily by the need for reintervention and not, fortunately for the patients, by amputation. Several studies of PAD have shown that open bypass patients have reduced risk of MALEs compared with those who undergo endovascular revascularizations, although these studies often include only CLI patients. [12] [13] [14] Currently, there are no high-quality data regarding 30-day outcomes after revascularizations for claudicants, particularly using the OPG definitions of MALEs. However, a study by Siracuse et al 15 compared longer term outcomes after LEB and IEI in those with superficial femoral artery disease. Their results suggested that LEB leads to greater 3-year freedom from restenosis compared with IEI (73% LEB vs 42% IEI) in addition to greater freedom [18] [19] [20] Tibial and redo revascularizations for claudication should therefore be undertaken with caution. Patients with these nonmodifiable risk factors must be counseled about the increased possibility of adverse limb outcomes in discussing the risks and benefits of conservative vs operative management of their claudication symptoms. Although the NSQIP does not have detailed anatomic data about vascular lesions, previous studies have suggested that in claudicants, restenosis and symptom recurrence are both predicted by lesions with higher TransAtlantic Inter-Society Consensus II (TASC II) classification. 15 The American Heart Association and TASC II document recommend that IEI should be considered for claudicants with focal, short atherosclerotic segments, whereas LEB should be considered for long-segment, diffuse disease. The quality of evidence regarding these recommendations has been called into question, however, and the Society for Vascular Surgery recommends that the decision of operative approach should be an individualized one based on the patient's anatomy, available conduit, risk factors, and preference. 3 LEB was associated with a twofold increase in 30-day MACEs compared with IEI patients. This difference was driven primarily by an increased rate of CVA and MI. The analysis by Siracuse et al comparing IEI and LEB in claudicants with superficial femoral artery disease did not find a difference in 30-day occurrence of MI or death between groups, although the complication rate was very low. Patients with PAD have disease that affects multiple vascular beds, not only those vessels located in the lower extremities; they are therefore known to be Limitations of this study include the short-term followup of the NSQIP data set. Although no conclusions can be made about longer term outcomes, it is important to define the expected rates of limb and cardiovascular outcomes in the immediate perioperative period. Furthermore, whereas MACEs typically occur in the early perioperative period, MALEs often do not occur until later in a patient's disease course. Although surgeons may focus on long-term patency, early loss of patency requiring reintervention is a fortunately rare event that becomes all the more important considering the low risk for limb loss with conservative management. The study is retrospective in nature, thereby limiting determination of causality of the investigated outcomes. The NSQIP does not provide details of vascular anatomy or imaging data, which would allow better comparison of patient groups. Furthermore, the NSQIP does not capture all IEIs performed at every participating institution as endovascular procedures performed by nonsurgeons are not reported. This underestimates the number of IEIs being performed nationally and potentially introduces bias into the patients' demographics, which in turn could affect the results of the analysis. Finally, the variables available for a multivariable model may not fully account for the multifactorial process of procedure selection, leaving some measure of selection bias.
CONCLUSIONS
This study helps establish the expected 30-day outcomes for LEB and IEI in the claudicant population using a large, national cohort of vascular patients. Although LEB and IEI have comparable 30-day rates of MALEs, the increased risk of claudication patients undergoing infrageniculate and redo revascularizations should trigger caution in proceeding with revascularization. This study also demonstrated that LEB patients experience 30-day MACEs twice as frequently as IEI patients do. Serious consideration of IEI should therefore be given to claudicants at high risk of cardiovascular morbidity when their anatomy is favorable. This analysis helps define contemporary outcomes after infrainguinal revascularizations performed for claudication and can serve as a baseline with which future studies can be compared. 
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